In addition, the secondary endpoints of the trial being examined are:
Rate of change of measured parameters
Rate of change in vital signs (blood pressure, heart rate, respiratory rate, saturation, and body temperature)
Time from the 1st day of receiving NLC-V treatment to negative RT-PCR test result
COVID-19 related deaths
Incidence and duration of time on supplemental oxygen
“I am glad that my pioneering academic work over the last 30 years on 3CL mechanisms has made such a significant impact, and that it is finally being recognized by leading pharmaceutical companies as a key target in the war against COVID-19 that could yield an easy to administer oral antiviral therapeutic capable of stopping SARS-CoV-2 replication, independent of different mutations that are emerging at the site of spike protein,” said Dr Dorit Arad, co-founder and chief scientific officer of NLC Pharma in a statement.
Israel
Jerusalem
Israel-general
Gerald-commissiong
Dorit-arad
Todos-medical-ltd
National-early-warning-score
Shaare-zedek-medical-center
இஸ்ரேல்
ஏருசலேம்
இஸ்ரேல்-ஜநரல்
தொரித்-ஆராட்